{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:08:10Z","timestamp":1785161290282,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-01986-1","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T04:18:50Z","timestamp":1752466730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk factors and outcomes of thyroid immune-related adverse events following PD-1\/PD-L1 inhibitors treatment in a large tertiary Chinese center"],"prefix":"10.1186","volume":"25","author":[{"given":"Wenwen","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaliang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"7","key":"1986_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389\u201399.","journal-title":"Nat Rev Endocrinol"},{"issue":"17","key":"1986_CR2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitors therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"},{"key":"1986_CR3","unstructured":"National cancer institute. Common terminology criteria for adverse events (CTCAE) v5.0 [EB\/OL]. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm 2017-11-27."},{"issue":"3","key":"1986_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","volume":"145","author":"P Arnaud-Coffin","year":"2019","unstructured":"Arnaud-Coffin P, Maillet D, Gan HK, Stelmes Jean-Jacques, You B, Dalle S, et al. A systematic review of aderse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 2019;145(3):639\u201348.","journal-title":"Int J Cancer"},{"issue":"2","key":"1986_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine gland injury following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173\u201382.","journal-title":"JAMA Oncol"},{"issue":"21","key":"1986_CR6","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"1986_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51(3):145\u201356.","journal-title":"Horm Metab Res"},{"issue":"2","key":"1986_CR8","first-page":"269","volume":"81","author":"NG Deligiannis","year":"2021","unstructured":"Deligiannis NG, Sosa S, Danilowicz K. Endocrine dysfunction induced by immune checkpoint inhibitors. Med (B Aires). 2021;81(2):269\u201378.","journal-title":"Med (B Aires)"},{"issue":"6","key":"1986_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer. 2018;124(6):1111\u201321.","journal-title":"Cancer"},{"key":"1986_CR10","doi-asserted-by":"publisher","first-page":"107296","DOI":"10.1016\/j.intimp.2020.107296","volume":"91","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Xia R, Xiao H, Pu D, Long Y, Ding Z, et al. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung. Int Immunopharmacol. 2021;91:107296.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"1986_CR11","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","volume":"9","author":"M Stelmachowska-Bana\u015b","year":"2020","unstructured":"Stelmachowska-Bana\u015b M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect. 2020;9(10):R207\u201328.","journal-title":"Endocr Connect"},{"issue":"1","key":"1986_CR12","first-page":"1","volume":"37","author":"Immune-endocrinology group","year":"2020","unstructured":"Immune-endocrinology group, Chinese society of endocrinology, Chinese medical association. Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events (2020). Chin J Endocrinol Metab. 2020;37(1):1\u201316.","journal-title":"Chin J Endocrinol Metab"},{"issue":"3","key":"1986_CR13","doi-asserted-by":"publisher","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","volume":"2","author":"M Girotra","year":"2018","unstructured":"Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2018;2(3):pky021.","journal-title":"JNCI Cancer Spectr"},{"issue":"7","key":"1986_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/thy.2016.0562","volume":"27","author":"Y Ichiro Yamauchi","year":"2017","unstructured":"Ichiro Yamauchi Y, Sakane Y, Fukuda T, Fujii D, Taura M, Hirata, et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid. 2017;27(7):894\u2013901.","journal-title":"Thyroid"},{"issue":"1","key":"1986_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17\u201365.","journal-title":"Endocr Rev"},{"issue":"2","key":"1986_CR16","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1093\/oncolo\/oyab043","volume":"27","author":"DF Lu","year":"2022","unstructured":"Lu DF, Yao J, Yuan GH, Gao Y, Zhang J, Guo X. Immune checkpoint inhibitor-related new-onset thyroid dysfunction: a retrospective analysis using the US FDA adverse event reporting system. Oncologist. 2022;27(2):e126\u201332.","journal-title":"Oncologist"},{"key":"1986_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","volume":"5","author":"MH Tan","year":"2019","unstructured":"Tan MH, Iyengar R, Mizokami-Stout K, Yentz S, MacEachern MP, Shen LY, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5:1.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"8","key":"1986_CR18","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017;102(8):2770\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 7","key":"1986_CR19","doi-asserted-by":"publisher","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","volume":"58","author":"SC Weinmann","year":"2019","unstructured":"Weinmann SC, Pisetsky DS. Mechanisms of immune related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology(Oxford). 2019;58(Suppl 7):vii59\u201367.","journal-title":"Rheumatology(Oxford)"},{"issue":"10","key":"1986_CR20","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1089\/thy.2017.0062","volume":"27","author":"Y Keiichi Torimoto","year":"2017","unstructured":"Keiichi Torimoto Y, Okada S, Nakayamada S, Kubo Y, Tanaka. Anti-PD-1 antibody therapy induces hashimoto\u2019s disease with an increase in peripheral blood follicular helper T cells. Thyroid. 2017;27(10):1335\u20136.","journal-title":"Thyroid"},{"issue":"3","key":"1986_CR21","first-page":"244","volume":"20","author":"HF Teng","year":"2007","unstructured":"Teng HF, Lv ZW, Jiang X, Cao CW, Hou M, Yang YH, et al. Clinical signification of detecting changes of serum thyroid hormones in levels patients with gastrointestinal cancer. J Radioimmunology. 2007;20(3):244\u20135.","journal-title":"J Radioimmunology"},{"key":"1986_CR22","doi-asserted-by":"crossref","unstructured":"\u00dclger S, \u00dclger Z, Yildiz F, Ozyar E. Incidence of hypothyroidism after radiotherapy for nasopharyngeal carcinoma. Med Oncol. 2007;24(1):91\u20134.","DOI":"10.1007\/BF02685908"},{"issue":"4","key":"1986_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","volume":"69","author":"M Grossmann","year":"2008","unstructured":"Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endorinol(Oxf). 2008;69(4):669\u201372.","journal-title":"Clin Endorinol(Oxf)"},{"issue":"2","key":"1986_CR24","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1210\/jc.2007-0586","volume":"92","author":"D Mannavola","year":"2007","unstructured":"Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, et al. A novel tyrosinekinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92(2):3531\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1986_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/thy.2006.0308","volume":"17","author":"E Wong","year":"2007","unstructured":"Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17(4):351\u20135.","journal-title":"Thyroid"},{"issue":"3","key":"1986_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Kasler MK, Stephens D, Rodriguez C, et al. Antibody-mediated thyroid gland injury during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"1986_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1210\/js.2017-00432","volume":"2","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc. 2018;2(3):241\u201351.","journal-title":"J Endocr Soc"},{"issue":"5","key":"1986_CR28","first-page":"1035","volume":"31","author":"M Toshiya Maekura","year":"2017","unstructured":"Toshiya Maekura M, Naito M, Tahara N, Ikegami Y, Kimura S, Sonobe, et al. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer. Vivo. 2017;31(5):1035\u20139.","journal-title":"Vivo"},{"issue":"8","key":"1986_CR29","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1007\/s10238-023-01082-5","volume":"23","author":"A Nervo","year":"2023","unstructured":"Nervo A, Ferrari M, Gruosso G, Migliore E, Basile S, D\u2019Angelo V, et al. Immune-related thyroid dysfunctions during anti PD-1\/PD-L1 inhibitors: new evidence from a single centre experience. Clin Exp Med. 2023;23(8):4817\u201324.","journal-title":"Clin Exp Med"},{"issue":"2","key":"1986_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M. PD\u2013L1 inhibitor\u2013induced thyroiditis is associated with better overall survival in cancer patients. Thyroid. 2020;30(2):177\u201384.","journal-title":"Thyroid"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01986-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01986-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01986-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:43:45Z","timestamp":1757231025000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01986-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01986-1","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Human Research Ethics Committee of Chinese PLA General Hospital (No. S2022-190-01). The authors confirm that all experiments were performed following the relevant Declaration of Helsinki. Informed consent was waived by our Institutional Review Board because of the retrospective nature of our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"171"}}